Inhibitor | Concentration | Relative Uptake | ||
---|---|---|---|---|
[3H]Mepyramine | [14C]Epinastine | |||
mM | % of control | |||
TEA | 5 | 93.4 ± 12.7 | 125 ± 11.9 | |
Guanidine | 5 | 96.5 ± 9.63 | 100 ± 10.6 | |
Benzoic acid | 10 | 86.3 ± 16.0 | 148 ± 49.4* | |
Carnitine | 5 | 101 ± 15.1 | 105 ± 15.0 | |
Quinidine | 0.01 | 92.5 ± 12.0 | 123 ± 1.44 | |
0.1 | 62.8 ± 5.69* | 96.1 ± 12.8 | ||
0.5 | 13.8 ± 3.70* | 66.1 ± 3.09 | ||
Amantadine | 0.1 | 80.6 ± 9.42 | 93.3 ± 10.6 | |
1 | 10.6 ± 0.852* | 60.1 ± 14.5* | ||
Verapamil | 0.1 | 59.1 ± 5.77* | 70.1 ± 9.74 | |
1 | 7.99 ± 2.20* | 41.8 ± 5.05* | ||
PAH | 1 | 95.9 ± 5.07 | 131 ± 2.49 | |
Estrone-3-sulfate | 0.5 | 102 ± 8.87 | 142 ± 7.55 | |
Taurocholate | 0.1 | 94.6 ± 12.1 | 89.8 ± 9.82 | |
Digoxin | 0.1 | 84.5 ± 4.27 | 133 ± 62.4 |
PAH, p-aminohippurate.
↵* Significantly different from the control by a two-sided Dunnett test (p < 0.05)